{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:29Z","timestamp":1787032769316,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,23]]},"DOI":"10.7759\/cureus.69979","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:58:17Z","timestamp":1727071097000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Low or Reduced Dose Direct Oral Anticoagulants Versus Dual Antiplatelet Therapy Following Left Atrial Appendage Closure: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Godfrey","family":"Tabowei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayez S","family":"Alreshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farook","family":"Ayyub Kantharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzah M","family":"Alghzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.11.010","article-title":"Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies","volume":"7","author":"Bajaj NS","year":"2014","unstructured":"Bajaj NS, Parashar A, Agarwal S, et al.. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. JACC Cardiovasc Interv. 2014, 7:296-304. 10.1016\/j.jcin.2013.11.010","journal-title":"JACC Cardiovasc Interv"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-023-00337-2","article-title":"Left atrial appendage closure: a narrative review","volume":"12","author":"Nagasaka T","year":"2023","unstructured":"Nagasaka T, Nakamura M. Left atrial appendage closure: a narrative review. Cardiol Ther. 2023, 12:615-635. 10.1007\/s40119-023-00337-2","journal-title":"Cardiol Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.949732","article-title":"Left atrial appendage exclusion in atrial fibrillation","volume":"9","author":"Rozen G","year":"2022","unstructured":"Rozen G, Margolis G, Marai I, et al.. Left atrial appendage exclusion in atrial fibrillation. Front Cardiovasc Med. 2022, 9:949732. 10.3389\/fcvm.2022.949732","journal-title":"Front Cardiovasc Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012812","article-title":"Antithrombotic management after left atrial appendage closure: current evidence and future perspectives","volume":"16","author":"Mesnier J","year":"2023","unstructured":"Mesnier J, Cepas-Guill\u00e9n P, Freixa X, Flores-Umanzor E, Hoang Trinh K, O'Hara G, Rod\u00e9s-Cabau J. Antithrombotic management after left atrial appendage closure: current evidence and future perspectives. Circ Cardiovasc Interv. 2023, 16:e012812. 10.1161\/CIRCINTERVENTIONS.122.012812","journal-title":"Circ Cardiovasc Interv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11174.1","article-title":"Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants","volume":"6","author":"Weitz JI","year":"2017","unstructured":"Weitz JI, Jaffer IH, Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res. 2017, 6:985. 10.12688\/f1000research.11174.1","journal-title":"F1000Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri S","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, et al.. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther. 2023, 40:41-66. 10.1007\/s12325-022-02333-9","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.shj.2024.100354","article-title":"Left atrial appendage occlusion: expanding indications and new developments [IN PRESS]","author":"Reed GW","year":"2024","unstructured":"Reed GW, Nakhla S, Miyasaka R, et al.. Left atrial appendage occlusion: expanding indications and new developments [IN PRESS]. Structural Heart. 2024, 10.1016\/j.shj.2024.100354","journal-title":"Structural Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion","volume":"14","author":"Della Rocca DG","year":"2021","unstructured":"Della Rocca DG, Magnocavallo M, Di Biase L, et al.. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv. 2021, 14:2353-2364. 10.1016\/j.jcin.2021.07.031","journal-title":"JACC Cardiovasc Interv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd8110142","article-title":"Low dose of direct oral anticoagulants after left atrial appendage occlusion","volume":"8","author":"Cepas-Guillen PL","year":"2021","unstructured":"Cepas-Guillen PL, Flores-Umanzor E, Regueiro A, et al.. Low dose of direct oral anticoagulants after left atrial appendage occlusion. J Cardiovasc Dev Dis. 2021, 8:142. 10.3390\/jcdd8110142","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"Duthoit G","year":"2020","unstructured":"Duthoit G, Silvain J, Marijon E, et al.. Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study. Circ Cardiovasc Interv. 2020, 13:e008481. 10.1161\/CIRCINTERVENTIONS.119.008481","journal-title":"Circ Cardiovasc Interv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","author":"Freixa X","year":"2024","unstructured":"Freixa X, Cruz-Gonz\u00e1lez I, Cepas-Guill\u00e9n P, et al.. Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial. JAMA Cardiol. 2024, 10.1001\/jamacardio.2024.2335","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12185955","article-title":"Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios","volume":"12","author":"Luc\u00e0 F","year":"2023","unstructured":"Luc\u00e0 F, Oliva F, Abrignani MG, et al.. Management of patients treated with direct oral anticoagulants in clinical practice and challenging scenarios. J Clin Med. 2023, 12:5955. 10.3390\/jcm12185955","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/dj4010005","article-title":"New direct oral anticoagulants (DOAC) and their use today","volume":"4","author":"Schwarb H","year":"2016","unstructured":"Schwarb H, Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J (Basel). 2016, 4:5. 10.3390\/dj4010005","journal-title":"Dent J (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12080","article-title":"The coagulation system in atherothrombosis: Implications for new therapeutic strategies","volume":"2","author":"Olie RH","year":"2018","unstructured":"Olie RH, van der Meijden PE, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018, 2:188-198. 10.1002\/rth2.12080","journal-title":"Res Pract Thromb Haemost"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2023.08.004","article-title":"Impact of factor Xa inhibition on coagulation, platelet reactivity, and thrombosis in patients with peripheral artery disease","volume":"97","author":"Hall RP","year":"2023","unstructured":"Hall RP, Majumdar M, Ferreira SS, et al.. Impact of factor Xa inhibition on coagulation, platelet reactivity, and thrombosis in patients with peripheral artery disease. Ann Vasc Surg. 2023, 97:211-220. 10.1016\/j.avsg.2023.08.004","journal-title":"Ann Vasc Surg"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY19M08_01","article-title":"EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update","volume":"15","author":"Glikson M","year":"2020","unstructured":"Glikson M, Wolff R, Hindricks G, et al.. EHRA\/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. EuroIntervention. 2020, 15:1133-1180. 10.4244\/EIJY19M08_01","journal-title":"EuroIntervention"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy VY","year":"2014","unstructured":"Reddy VY, Sievert H, Halperin J, et al.. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014, 312:1988-1998. 10.1001\/jama.2014.15192","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes DR Jr","year":"2014","unstructured":"Holmes DR Jr, Kar S, Price MJ, et al.. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014, 64:1-12. 10.1016\/j.jacc.2014.04.029","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2019.11.009","article-title":"Short-term antiplatelet versus anticoagulant therapy after left atrial appendage occlusion: a systematic review and meta-analysis","volume":"6","author":"Osman M","year":"2020","unstructured":"Osman M, Busu T, Osman K, Khan SU, Daniels M, Holmes DR, Alkhouli M. Short-term antiplatelet versus anticoagulant therapy after left atrial appendage occlusion: a systematic review and meta-analysis. JACC Clin Electrophysiol. 2020, 6:494-506. 10.1016\/j.jacep.2019.11.009","journal-title":"JACC Clin Electrophysiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and clinical impact of\u00a0device-related thrombus following\u00a0percutaneous left\u00a0atrial\u00a0appendage occlusion: a meta-analysis","volume":"4","author":"Alkhouli M","year":"2018","unstructured":"Alkhouli M, Busu T, Shah K, Osman M, Alqahtani F, Raybuck B. Incidence and clinical impact of\u00a0device-related thrombus following\u00a0percutaneous left\u00a0atrial\u00a0appendage occlusion: a meta-analysis. JACC Clin Electrophysiol. 2018, 4:1629-1637. 10.1016\/j.jacep.2018.09.007","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/293732-efficacy-and-safety-of-low-or-reduced-dose-direct-oral-anticoagulants-versus-dual-antiplatelet-therapy-following-left-atrial-appendage-closure-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:58:19Z","timestamp":1727071099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/293732-efficacy-and-safety-of-low-or-reduced-dose-direct-oral-anticoagulants-versus-dual-antiplatelet-therapy-following-left-atrial-appendage-closure-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.69979","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}